Noxopharm Ltd has released a press release.
Sofra breakthrough science publish in major medical journal
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- December 2025 Quarterly Activities Report and Appendix 4C
- HERACLES clinical trial successfully completed
- HERACLES clinical trial Update 5
- First dose in HERACLES clinical trial Part Two
- Second part of HERACLES clinical trial begins
Later from Noxopharm
- At-the-Market (ATM) agreement with Acuity Capital
- R&D rebate strengthens cash position
- Appendix 4D and FY2026 Half Year Financial Report
- Resignation of Chief Executive Officer
- Noxopharm appoints Dr Olivier Laczka as new CEO
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm